PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 28(6): 632-636
2008
© 2008 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Yang, W.-S.
Right arrow Articles by Wu, K.-D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, W.-S.
Right arrow Articles by Wu, K.-D.

Clinical

LERCANIDIPINE-INDUCED CHYLOPERITONEUM IN PATIENTS ON PERITONEAL DIALYSIS

Wei-Shun Yang1, Jenq-Wen Huang2, Huei-Wen Chen3, Tun-Jun Tsai2 and Kwan-Dun Wu2

Department of Internal Medicine,1 Taoyuan General Hospital, Taoyuan County; Department of Internal Medicine2 and Department of Nursing,3 National Taiwan University Hospital Taipei, Taiwan

Correspondence to: K.D. Wu, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan. kdwu{at}ntuh.gov.tw

{diamondsuit} Objective: Lercanidipine is a lipophilic calcium channel blocker and a widely used antihypertensive agent. However, it can cause chyloperitoneum in patients receiving peritoneal dialysis (PD). The incidence, pathophysiology, and clinical impact of these adverse events are not known.

{diamondsuit} Design: Retrospective study.

{diamondsuit} Method: Patients were screened for use of antihypertensive agents. Those that had taken lercanidipine were identified and dialysate cholesterol (Chol) and triglyceride (TG) levels were checked. Serum levels were taken from the routine biochemistry record closest to the time of the dialysate levels. Dialysate Chol and TG from patients on other antihypertensives and with matched serum lipid profiles were compared.

{diamondsuit} Patients: 14 of 222 patients had taken lercanidipine during February 2005 to January 2006, accounting for 12% of all patients on calcium channel blockers in our PD center.

{diamondsuit} Results: Of 14 patients prescribed lercanidipine, 8 (57%) developed chyloperitoneum. None had peritonitis and the dialysate was clear under microscopic examination. Mean dialysate TG was 128.4 ± 133.0 mg/dL and mean dialysate Chol was 18.2 ± 24.9 mg/dL in patients that developed chyloperitoneum. These patients were also noted to have higher blood TG and Chol than patients that did not develop chyloperitoneum. In contrast, patients on other antihypertensive agents with matched blood TG and Chol levels had low dialysate TG levels and zero dialysate Chol.

{diamondsuit} Conclusion: Lercanidipine frequently causes chyloperitoneum in Taiwanese PD patients. The risk of developing this adverse event seems to be related to the blood lipid profile. The mechanism of this phenomenon is worthy of further investigation.

KEY WORDS: Chyloperitoneum; hyperlipidemia; lercanidipine.

Received 18 January 2008; accepted 1 April 2008.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2008 by Multimed Inc.